Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Research & Development (2016 - 2025)

Historic Research & Development for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to $1.4 million.

  • Palisade Bio's Research & Development fell 9128.75% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 11313.65%. This contributed to the annual value of $9.1 million for FY2024, which is 3148.12% up from last year.
  • Per Palisade Bio's latest filing, its Research & Development stood at $1.4 million for Q3 2025, which was down 9128.75% from $1.7 million recorded in Q2 2025.
  • Palisade Bio's 5-year Research & Development high stood at $16.0 million for Q3 2024, and its period low was -$6.9 million during Q4 2024.
  • Its 5-year average for Research & Development is $1.8 million, with a median of $1.4 million in 2023.
  • The largest annual percentage gain for Palisade Bio's Research & Development in the last 5 years was 66045.63% (2024), contrasted with its biggest fall of 60598.1% (2024).
  • Palisade Bio's Research & Development (Quarter) stood at $624000.0 in 2021, then soared by 275.48% to $2.3 million in 2022, then plummeted by 41.49% to $1.4 million in 2023, then tumbled by 605.98% to -$6.9 million in 2024, then surged by 120.1% to $1.4 million in 2025.
  • Its Research & Development was $1.4 million in Q3 2025, compared to $1.7 million in Q2 2025 and $950000.0 in Q1 2025.